Selinexor Treatment of Refractory Myeloma (STORM)
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Sponsor: Karyopharm Therapeutics Inc
A PHASE2 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Karyopharm Therapeutics Inc and has accumulated 26 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
26 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Feb 2023 [monthly]
Completed PHASE2
▶ Show 21 earlier versions
-
Jan 2022 — Mar 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Sep 2020 — Dec 2020 [monthly]
Completed PHASE2
-
Mar 2020 — Sep 2020 [monthly]
Completed PHASE2
-
Dec 2019 — Mar 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Karyopharm Therapeutics Inc
For direct contact, visit the study record on ClinicalTrials.gov .